Effect of Inhibitors of the Proton Pump on Intestinal Transporters
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Dabigatran etexilate is a novel oral anticoagulant. It is indicated in venous thromboembolic
prevention in orthopedic surgery and has recently shown greater efficiency and tolerance as
anticoagulants in preventing thromboembolism in atrial fibrillation. However, it increases
the risk of gastrointestinal bleeding compared to standard treatment (AVK) [3]. In these
circumstances the risk / benefit of dabigatran could be improved by combining it with gastric
protectors such as inhibitor drugs proton pump (IPP).
Investigators want to evaluate the pharmacokinetic and pharmacodynamic effects of
co-administration of these two IPP (omeprazole, rabeprazole) with dabigatran in healthy
subjects.